Pure Global AI
NCT06249828Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti^® in Knee Cartilage Defects

A Clinical Trial to Evaluate the Efficacy and Safety of Cartilage Regeneration in the Use of MegaCarti^® in Patients With Knee Joint Cartilage Injury: Multicenter, Independent Evaluator-subject Blinded, Microfracture-comparative, Randomized Clinical Study
L&C BioClinicalTrials.govdeviceDevice trial
Study focus
Disease/Condition
Osteoarthritis, Knee
Drug/Device/Intervention
MegaCarti^®
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
L&C Bio
Location
Gyeonggi-do,Gyeonggi-do,Seoul,Seoul, South Korea
Timeline & enrollment
Phase
N/A
Start date
Jan 22, 2024
End date
Apr 30, 2025
Enrollment
60 participants
Primary outcome

MOCART score

Summary

Subjects aged 50 to 65 years with knee cartilage defects will undergo microfracture treatment
 for cartilage regeneration and MegaCarti^® will be applied.

ICD-10 classifications
Chronic instability of kneeInjuries to the knee and lower legGonarthrosis [arthrosis of knee]Dislocation, sprain and strain of joints and ligaments of kneeSprain and strain of other and unspecified parts of knee
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06249828
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06249828 through Pure Global AI's free database. This phase not specified trial is sponsored by L&C Bio and is currently Recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.